428 related articles for article (PubMed ID: 16964201)
1. Biotech R&D goes further afield.
Lawrence S
Nat Biotechnol; 2006 Sep; 24(9):1052. PubMed ID: 16964201
[No Abstract] [Full Text] [Related]
2. Biotech slumps in Q1.
Lawrence S
Nat Biotechnol; 2008 May; 26(5):486. PubMed ID: 18464769
[No Abstract] [Full Text] [Related]
3. Does biotech M&A benefit investors?
Jacobs T
Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
[No Abstract] [Full Text] [Related]
4. The 802 million dollars fallacy.
Hodgson J
Nat Biotechnol; 2004 Sep; 22(9):1076. PubMed ID: 15340464
[No Abstract] [Full Text] [Related]
5. A rollercoaster ride.
Jacobs T
Nat Biotechnol; 2006 Mar; 24(3):284. PubMed ID: 16525390
[No Abstract] [Full Text] [Related]
6. Biotech drug market steadily expands.
Lawrence S
Nat Biotechnol; 2005 Dec; 23(12):1466. PubMed ID: 16333279
[No Abstract] [Full Text] [Related]
7. Biotech's wellspring: the health of private biotech in 2012.
Huggett B
Nat Biotechnol; 2013 May; 31(5):396-403. PubMed ID: 23657390
[No Abstract] [Full Text] [Related]
8. Public biotech 2010--the numbers.
Huggett B; Hodgson J; Lähteenmäki R
Nat Biotechnol; 2011 Jul; 29(7):585-91. PubMed ID: 21747381
[No Abstract] [Full Text] [Related]
9. Biotech financing retrenches in Q2.
Lawrence S
Nat Biotechnol; 2006 Aug; 24(8):883. PubMed ID: 16900116
[No Abstract] [Full Text] [Related]
10. Biotech as an employer.
Lawrence S
Nat Biotechnol; 2007 Jan; 25(1):12. PubMed ID: 17211380
[No Abstract] [Full Text] [Related]
11. Japanese firms broaden investment focus to early biotech.
Louët S; Sipp D
Nat Biotechnol; 2004 Aug; 22(8):931-2. PubMed ID: 15286631
[No Abstract] [Full Text] [Related]
12. Enthusiasm cools in Q2.
Lawrence S
Nat Biotechnol; 2005 Aug; 23(8):914. PubMed ID: 16082352
[No Abstract] [Full Text] [Related]
13. The biotech drug market.
Lawrence S
Nat Biotechnol; 2004 Dec; 22(12):1496. PubMed ID: 15583645
[No Abstract] [Full Text] [Related]
14. Biotech business Down Under.
Beckley C
Nature; 2004 Jun; 429(6991 Suppl):5-9. PubMed ID: 15175704
[No Abstract] [Full Text] [Related]
15. Biotech round the world: focus on Canada.
Biotechnol J; 2008 Jul; 3(7):848-51. PubMed ID: 18624341
[No Abstract] [Full Text] [Related]
16. Public biotech 98: the numbers.
Lähteenmäki R; Michael A; Marshall A
Nat Biotechnol; 1999 May; 17(5):429-32. PubMed ID: 10331795
[No Abstract] [Full Text] [Related]
17. Biotech blockbusters consolidate markets.
Lawrence S
Nat Biotechnol; 2006 Dec; 24(12):1466. PubMed ID: 17160033
[No Abstract] [Full Text] [Related]
18. IPOs break $1 billion in Q2.
Lawrence S
Nat Biotechnol; 2007 Aug; 25(8):833. PubMed ID: 17687349
[No Abstract] [Full Text] [Related]
19. Just how good an investment is the biopharmaceutical sector?
Thakor RT; Anaya N; Zhang Y; Vilanilam C; Siah KW; Wong CH; Lo AW
Nat Biotechnol; 2017 Dec; 35(12):1149-1157. PubMed ID: 29220034
[TBL] [Abstract][Full Text] [Related]
20. Biotech R&D still reeling.
Lawrence S
Nat Biotechnol; 2004 Sep; 22(9):1068. PubMed ID: 15340460
[No Abstract] [Full Text] [Related]
[Next] [New Search]